No Net Benefit of #Aducanumab for Alzheimer’s Disease, Panel Rules
▻https://www.medscape.com/viewarticle/954909
An influential, independent panel unanimously voted that aducanumab (Aduhelm) offers no benefit for patients with Alzheimer’s disease (AD), adding to growing opposition from medical experts to the US Food and Drug Administration’s (FDA’s) approval of this controversial drug.
The Institute for Clinical and Economic Review (ICER) asked one of its expert panels, the California Technology Assessment Forum, to consider the available data about aducanumab and requested that members vote on whether there was sufficient evidence of a net benefit of aducanumab plus supportive care vs supportive care alone. All 15 panelists voted no.